Cutler Group’s Aclaris Therapeutics ACRS Stock Holding History

Cutler Group’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,700	Closed	-$1K	–	5582
2021 Q1	$1K	Buy	+2,700	New	+$52.8K	﹤0.01%	5107
2019 Q4	–	Sell	-8,500	Closed	-$32K	–	3893
2019 Q3	$32K	Sell	8,500 -1,000	-11%	-$1.42K	﹤0.01%	1835
2019 Q2	$29K	Buy	9,500 +8,500	+850%	+$46.3K	﹤0.01%	1918
2019 Q1	$3K	Hold	1,000	–	–	﹤0.01%	3140
2018 Q4	$7K	Buy	+1,000	New	+$10.3K	﹤0.01%	2704

Other funds holding ACRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Cutler Group's ACRS Position: Q3 2021 in Review

Cutler Group sold out of Aclaris Therapeutics (ACRS) in Q3 2021, closing a stake of 600 shares — an estimated $10K sold.

Cutler Group first reported a position in ACRS in Q3 2017 and held it in 15 quarters. The position peaked at $73K in Q1 2021. 126 funds tracked by Wall St. Rank hold ACRS as of Q3 2021.

Cutler Group reported no remaining Aclaris Therapeutics position as of Q3 2021 after selling out during the quarter.
Cutler Group sold 600 Aclaris Therapeutics shares in Q3 2021, an estimated $10K.
Cutler Group first reported a position in Aclaris Therapeutics in Q3 2017 and held it in 15 quarters.
Cutler Group's Aclaris Therapeutics position peaked at $73K in Q1 2021.
126 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2021.

Based on Cutler Group's 13F filing for Q3 2021, filed 26 Oct 2021.